Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87

Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics (NASDAQ: VKTX) and increased the price target from $83 to $87. This adjustment reflects a positive outlook for the company's performance in the market.